➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Express Scripts
Baxter
Medtronic
McKinsey
Mallinckrodt

Last Updated: January 18, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for Patritumab

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Patritumab?

Patritumab is an investigational drug.

There have been 9 clinical trials for Patritumab. The most recent clinical trial was a Phase 1 trial, which was initiated on March 1st 2014.

The most common disease conditions in clinical trials are Carcinoma, Non-Small-Cell Lung, Breast Neoplasms, and Lung Neoplasms. The leading clinical trial sponsors are Daiichi Sankyo Inc., Daiichi Sankyo, Inc., and SCRI Development Innovations, LLC.

There are eight US patents protecting this investigational drug and one hundred and ninety-six international patents.

Recent Clinical Trials for Patritumab
TitleSponsorPhase
A Study of U3-1402 in Subjects With Metastatic Breast CancerDaiichi Sankyo, Inc.Phase 2
A Study of U3-1402 in Subjects With Metastatic Breast CancerSCRI Development Innovations, LLCPhase 2
Patritumab Deruxtecan in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung CancerDaiichi Sankyo, Inc.Phase 1

See all Patritumab clinical trials

Clinical Trial Summary for Patritumab

Top disease conditions for Patritumab
Top clinical trial sponsors for Patritumab

See all Patritumab clinical trials

US Patents for Patritumab

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Patritumab   Start Trial Multispecific constructs AbbVie Stemcentrx LLC (North Chicago, IL)   Start Trial
Patritumab   Start Trial Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein CureVac AG (Tubingen, DE)   Start Trial
Patritumab   Start Trial Binding-triggered transcriptional switches and methods of use thereof The Regents of the University of California (Oakland, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Express Scripts
Baxter
Medtronic
McKinsey
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.